Details of Disease

General Information of Disease (ID: DISNCK1H)

• Disease Name: Haematopoietic/lymphoid cancer
• Disease Class: 2B33: Malignant haematopoietic neoplasm
• Disease Hierarchy:
  DIS01GPL: Grass pollen hypersensitivity
  DISNCK1H: Haematopoietic/lymphoid cancer
• ICD Code:
  ICD-11: ICD-11: 2B33.5
  ICD-10: ICD-10: C85.9
• Disease Identifiers:
  MONDO ID: MONDO_0002334
  UMLS CUI: C1512393
  MedGen ID: 268180

Drug-Interaction Atlas (DIA) of This Disease

This Disease is Treated as An Indication in 8 Clinical Trial Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
CART-19	DMHQKN6	Phase 2	CAR T Cell Therapy	[1]
Anti-CD19 CAR-T	DM04HNB	Phase 1/2	CAR T Cell Therapy	[2]
Anti-CD19-CAR vector-transduced T cells	DMQXU4C	Phase 1/2	CAR T Cell Therapy	[3]
Anti-CD20-CAR vector-transduced autologous T cells	DMCDUJY	Phase 1/2	CAR T Cell Therapy	[4]
CD19-TCRz-41BB and CD22-TCRz-41BB CAR-T Cells	DM4MBUI	Phase 1/2	CAR T Cell Therapy	[5]
SHR2554	DMMUCH0	Phase 1/2	Small molecular drug	[6]
BP1002	DMI826O	Phase 1	Antisense oligonucleotide	[7]
CD33-CAR-T Cell	DMYD31U	Phase 1	CAR T Cell Therapy	[8]

Molecular Interaction Atlas (MIA) of This Disease

References

• [1] ClinicalTrials.gov (NCT01029366) CART19 to Treat B-Cell Leukemia or Lymphoma That Are Resistant or Refractory to Chemotherapy
• [2] ClinicalTrials.gov (NCT02685670) Competitive Transfer of CD19-TCRz-CD28 and CD19-TCRz-CD137 CAR-T Cells for B-cell Leukemia/Lymphoma
• [3] ClinicalTrials.gov (NCT01864889) Treatment of Relapsed and/or Chemotherapy Refractory B-cell Malignancy by CART19
• [4] ClinicalTrials.gov (NCT01735604) Genetically Engineered Lymphocyte Therapy in Treating Patients With Lymphoma That is Resistant or Refractory to Chemotherapy
• [5] ClinicalTrials.gov (NCT02903810) Combination Transfer of CD19-TCRz-41BB and CD22-TCRz-41BB CAR-T Cells for B-cell Hematologic Malignancy
• [6] ClinicalTrials.gov (NCT03603951) A Phase 1 Study of SHR2554 in Subjects With Relapsed or Refractory Mature Lymphoid Neoplasms. U.S. National Institutes of Health.
• [7] ClinicalTrials.gov (NCT04072458) A Clinical Trial of BP1002 in Patients With Advanced Lymphoid Malignancies. U.S. National Institutes of Health.
• [8] ClinicalTrials.gov (NCT03126864) Study of Adoptive Cellular Therapy Using Autologous T Cells Transduced With Lentivirus to Express a CD33 Specific Chimeric Antigen Receptor in Patients With Relapsed or Refractory CD33-Positive Acute Myeloid Leukemia